Epigenetics: Reprogramming cancer - overcoming drug resistance | 11th 4SC Scientific Symposium
Internationally renowned experts to present and discuss recent developments in the field of epigenetic cancer therapy
The Symposium will feature 7 lectures by internationally renowned scientists and clinicians covering the latest research on epigenetic mechanisms in health and disease, novel methods to track epigenetic modulation in cells and (combined) epigenetic treatment strategies to overcome drug resistance in cancer.
The keynote lecture will be given by Prof Thomas Jenuwein, Director and Senior Group Leader at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, and member of 4SC's recently established international Scientific Expert Panel. Prof Thomas Jenuwein states: "Epigenetic malfunction is a key to the development of cancer, as it significantly influences the timing and aggressiveness of the disease. In my lecture I will focus on the epigenetic activity of repetitive elements in mammalian DNA - formerly considered as inert evolutionary or viral relics - and their possible function for normal development and disease."
"Despite recent advances in oncology, resistance and disease progression on or after therapeutic intervention are still serious problems", adds Dr Erich Enghofer, organizer of the Symposium and 4SC's Executive Vice President Oncology and Hematology. "I am very proud that 4SC is holding this high-level conference with outstanding speakers who are highly recognized in their respective fields of research. We are looking forward to productive discussions on recent advances in the field of epigenetics and drug development overcoming drug resistance."
Speakers and Abstracts
Prof Thomas Jenuwein, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany | Epigenetic Control of the Genome by Repetitive Elements
Prof Christoph Plass, German Cancer Research Center, Heidelberg, Germany | Cancer: Cell-of-Origin and Epigenetics
Dr Charles B. Epstein, Broad Institute of MIT and Harvard, Cambridge, MA, USA | Mapping and Analysis of Chromatin Regulators
Dr Jun Qi, Dana-Farber, Boston, MA, USA | Bromodomain-Inhibition with JQ1 as Therapeutic Strategy in Oncology
Prof Andreas Neubauer, University Clinics Marburg-Gießen, Germany | Epigenetic Modifiers as Anti-Cancer Agents: Today and Tomorrow
Prof Alexander Tarakhovsky, Rockefeller University, New York, NY, USA | Epigenetic Control of Antiviral Response and Inflammation
Dr Daniel Vitt, 4SC, Planegg-Martinsried, Germany | Targeting Transcriptional Dysregulation with Epigenetic Modifiers
About epigenetic cancer therapy
Epigenetic changes modify the activation of certain genes, but not the genetic code of DNA itself, causing activation or silencing of genes. This mechanism enables differentiated cells such as those in the lungs, nerves or skin to serve very different functions despite containing identical genetic code.
Epigenetic alterations are as important as genetic mutations in a cell's transformation to cancer, and their manipulation holds great promise for cancer therapy. Epigenetic compounds such as 4SC's resminostat and 4SC-202 may convert these epigenetic alterations back to normal. For example, treatment with epigenetic cancer compounds interrupts or combats the mechanism that is responsible for the onset of cancer, makes cancer cells visible to the body's own immune system or renders them more responsive to immuno-oncological treatment.
Epigenetics is considered as a future growth market in the field of Oncology based on its significant promise as both a monotherapy and in combined approaches with immuno-oncology drugs and other therapeutic agents. In an October 2015 report by business information publisher Grand View Research, the worldwide epigenetics market was projected to generate revenues of US-$16 billion in 2022, up from US-$ 4 billion in 2014.
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
About 4SC AG
4SC (www.4sc.com) is a biotech company dedicated to the research and development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options for cancer patients that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 50 employees as of 30 June 2016. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.